{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T12:28:18Z","timestamp":1785068898322,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/nrgastro.2017.28","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T05:17:44Z","timestamp":1489555064000},"page":"264-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MicroRNA antagonists: promising antiviral agents against HCV and other viruses?"],"prefix":"10.1038","volume":"14","author":[{"given":"Jean-Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"BFnrgastro201728_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrg3162","volume":"13","author":"AE Pasquinelli","year":"2012","unstructured":"Pasquinelli, A. E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271\u2013282 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrgastro201728_CR2","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.1073\/pnas.0704894104","volume":"104","author":"G Randall","year":"2007","unstructured":"Randall, G.  et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104, 12884\u201312889 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro201728_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-virology-110615-042409","volume":"3","author":"P Sarnow","year":"2016","unstructured":"Sarnow, P. & Sagan, S. M. Unraveling the mysterious interactions between hepatitis C virus RNA and liver-specific microRNA-122. Annu. Rev. Virol. 3, 309\u2013332 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"BFnrgastro201728_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen, H. L.  et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685\u20131694 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201728_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","volume":"389","author":"MH van der Ree","year":"2017","unstructured":"van der Ree, M. H.  et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1b, double-blind, randomized controlled trial. Lancet 389, 709\u2013717 (2017).","journal-title":"Lancet"},{"key":"BFnrgastro201728_CR6","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash, T. P.  et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796\u20138807 (2014).","journal-title":"Nucleic Acids Res."},{"key":"BFnrgastro201728_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.antiviral.2014.02.008","volume":"105","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky, J. M. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antiviral Res. 105, 22\u201325 (2014).","journal-title":"Antiviral Res."},{"key":"BFnrgastro201728_CR8","doi-asserted-by":"publisher","first-page":"32015","DOI":"10.1074\/jbc.M109.016774","volume":"284","author":"S Bai","year":"2009","unstructured":"Bai, S.  et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284, 32015\u201332027 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrgastro201728_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1172\/JCI63455","volume":"122","author":"WC Tsai","year":"2012","unstructured":"Tsai, W. C.  et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884\u20132897 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrgastro201728_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.gastro.2016.08.043","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky, J. M. Hepatitis C drugs: is next generation the last generation? Gastroenterology 151, 587\u2013590 (2016).","journal-title":"Gastroenterology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.28","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrgastro.2017.28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:58:15Z","timestamp":1684468695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2017.28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFnrgastro201728"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2017.28","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]},"assertion":[{"value":"15 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-M.P. has received research grants from Abbvie and Gilead. He has served as an adviser and speaker for Abbvie, Bristol-Myers Squibb, Gilead, Janssen and Merck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}